<span item_type="fundamental" item_id="3c833c999012c00ae5607a4214788a61" counter_id="ST/US/CPIX" env="prod"></span><span item_type="announcement" item_id="513217465863439361" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 11.71 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD 0.08.</p><p>EBIT: As of FY2025 Q1, the actual value is USD 1.254 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Cumberland Pharmaceuticals Inc. reported net revenues of $11.7 million for the first quarter of 2025, marking a 38% increase compared to the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm"></span></li><li>Revenue breakdown includes $3.5 million from Kristalose®, $2.3 million from Sancuso®, $1.4 million from Vibativ®, and $1.3 million from Caldolor®.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net income for the first quarter of 2025 was approximately $1.3 million, compared to a net loss of $1.9 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm"></span></li><li>Operating income was $1.3 million, a significant improvement from an operating loss of $1.9 million in the first quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm"></span></li><li>Total operating expenses for the quarter were $10.4 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash flow from operations was $3.9 million for the first quarter of 2025, compared to - $2.1 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabilities, and $28.7 million of shareholders’ equity.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Cumberland Pharmaceuticals is optimistic about future growth driven by strong performance from approved brands, expansion of international partnerships, progress in clinical development programs, and potential strategic acquisitions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/a2025q1-ex991er.htm"></span></li></ul>

Cumberland Pharma | 8-K: FY2025 Q1 Revenue: USD 11.71 M